Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISC 2023 | Defining the limits of EVT: MeVOs

Marc Ribo, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, outlines the ongoing efforts to determine the safety and efficacy of endovascular therapy (EVT) in acute ischemic stroke due to medium vessel occlusion (MeVO). While the value of EVT for large vessel occlusion strokes has been definitively demonstrated, the risk-benefit ratio in MeVO cases is less cut and dried. Symptoms are typically less severe in MeVO cases and the EVT procedure is more difficult to perform, giving a higher risk of complications. Several large-scale clinical trials are ongoing, which aim to define the limits for EVT use in distal vessel occlusions. This interview took place during the International Stroke Conference (ISC) 2023 in Dallas, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


MR is a consultant for Apta Targets.